PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsStavudine
Zerit(stavudine)
Zerit (stavudine) is a small molecule pharmaceutical. Stavudine was first approved as Zerit on 1994-06-24. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Stavudine
Tradename
Company
Number
Date
Products
ZERITBristol Myers SquibbN-020412 DISCN1994-06-24
5 products, RLD
ZERITBristol Myers SquibbN-020413 DISCN1996-09-06
1 products, RLD
ZERIT XRBristol Myers SquibbN-021453 DISCN2002-12-31
4 products
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF04: Stavudine
J05AR: Antivirals for treatment of hiv infections, combinations
J05AR07: Stavudine, lamivudine and nevirapine
HCPCS
No data
Clinical
Clinical Trials
172 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201652362132152
Acquired immunodeficiency syndromeD000163EFO_0000765B20266113
HivD006678O98.71226212
TuberculosisD014376EFO_0000774A15-A1913216
LipodystrophyD008060HP_0009125E88.1235
Cryptococcal meningitisD016919EFO_0007228B45.1112
Lactic acidosisD000140HP_0003128E87.201112
Hiv-1D01549711
HepatitisD006505HP_0012115K75.911
ExanthemaD005076HP_000098811
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B5411
Aids-associated nephropathyD016263EFO_000731311
DiarrheaD003967HP_0002014R19.711
Aids dementia complexD015526EFO_000260811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv seropositivityD00667911
Metabolic diseasesD008659EFO_0000589E88.911
Metabolic syndromeD024821EFO_0000195E88.81011
Nutrition disordersD009748EFO_000106911
Insulin resistanceD007333HP_0000855E88.81911
HyperlactatemiaD06590611
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526B19.211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameStavudine
INNstavudine
Description
Stavudine is a nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase It has a role as an antimetabolite, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral agent. It is an organic molecular entity, a nucleoside analogue and a dihydrofuran. It is functionally related to a thymine.
Classification
Small molecule
Drug classantineoplastics; antivirals (zidovudine group) (exception: edoxudine)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
Identifiers
PDB
CAS-ID3056-17-5
RxCUI
ChEMBL IDCHEMBL991
ChEBI ID63581
PubChem CID18283
DrugBankDB00649
UNII IDBO9LE4QFZF (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Stavudine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,751 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,447 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use